key: cord-1012165-z8e3qtkg
authors: Pathanki, Adithya M.; Mirza, Darius F.
title: Liver transplantation during the times of COVID-19 – viruses, vaccines and beyond
date: 2021-05-04
journal: J Clin Exp Hepatol
DOI: 10.1016/j.jceh.2021.04.014
sha: 3ab71880275948024a8b38644aa47bc0f10f08e3
doc_id: 1012165
cord_uid: z8e3qtkg

nan

The ongoing COVID-19 pandemic has had unprecedented effects on the care of patients with liver disease due to a loss of resources, personnel and donors. It led to a glut of communication, in a massive global effort of coordinated scientific collaboration. This was initially led by experts from China and Italy which saw the first peaks in COVID-19 and has since been supplemented by various professional bodies on liver disease and liver transplant (LT) across the world [1] [2] [3] . Within the field of liver transplantation, a multitude of guidelines have been published with respect to various aspects, the commonest topic being the impact of COVID infection in LT recipients 2 . However, there has also been acknowledgement that different centres have dealt with the pandemic differently 4 . Western literature has also acknowledged the ethical challenges in transplantation during the pandemic with many centres trying to balance distributive justice, patient autonomy and beneficence on the basis of their individual position on the pandemic curve, as well as the logistic challenges created by a severely depleted ICU resource that has been one of the main constraints over a 12 month period. 5 The article by Soin et al., highlights these challenges faced in the Indian scenario, where traditionally, the burden of transplantation is carried by live donors 6 . Broadly, it is interesting to note that similar patterns emerge in dealing with donor and recipient management with respect to COVID-19.

General hospital based measures in the article by Soin et al., are particularly similar to the measures adopted at our centre in the UK as well 6 . These include minimising footfall in the hospital by shifting all possible outpatient appointments to virtual consultations, routine screening of healthcare staff and patients, creation of a "clean" pathway for patients recently screened negative for COVID-19 and strict adherence to mandatory measures like the use of masks and regular use of hand sanitizers / hand washing. Visiting remains suspended in all hospitals across the UK on the day of writing, with privileges granted only for relatives of patients who are in the palliative setting or those who have complex care needs provided by their relatives (e.g. significant learning difficulties).

In the deceased donor setting, the screening of donors for COVID-19 has been the cornerstone of safety. NHSBT (NHS Blood and Transplant), the regulatory body for transplantation in the UK, recommends at least three negative RT-PCR swabs (one being from an endotracheal aspirate) before being considered for donation. The early opinion was to always refuse organs from those with an acute respiratory syndrome secondary to COVID-19 7 , however, recent evidence has raised the possibility of accepting non-lung solid organs for transplantation based on the fact that RNA viruses have not been isolated in non-lung solid organs and that organs from patients infected with other respiratory RNA viruses are routinely used in transplantation 7 . In the live donor setting, as reported by the Soin et al., the testing is elective and as close to the donor operation as logistically feasible to ensure safety and protection 6 .

The screening of the liver recipient is slightly more complex with a few more factors to be taken into account. These include the need for transplantation, and the assessments (clinical, biochemical and radiological) that come along with that before considering the actual operation itself. While recipients with an acute COVID-19 syndrome are generally considered unfit for liver transplantation, it has been deemed safe for transplantation to proceed after resolution of the COVID-19 positive status 8 .

Across the first wave of the pandemic, 157 liver transplants were performed in the UK across the seven centres 9 . These were on the back of measures implemented that were not dissimilar to those outlined by Soin et al 6 . This was on the background of an 86% reduction in donor activity and 84% reduction in liver transplantation activity. Most were carried out from a prioritized "clinically urgent" list of patients that was collated nationally and updated regularly 9 Prioritisation of paediatric centres also helped ease the waitlist burden in the UK. This was possible because of the relatively lower COVID disease burden on paediatric intensive care unit settings 10 , where it was possible to protect resources. It allowed some "small adult recipients" to be transplanted as "large paediatric recipients". For example, at our centre, three teenaged recipients underwent whole liver graft transplantation due to a lack of adult recipients / intensive care capacity.

Other miscellaneous measures worth highlighting include the use of other preservation techniques such as normothermic machine perfusion to allow for prolonged logistic times, in an attempt to overcome delays in ICU resource provision and the use of multi-visceral and bowel grafts for paediatric recipients when feasible. Indeed, during the first wave, 31 split liver transplants were carried out in the UK, and soon after that, five intestinal / multi-visceral (liver, pancreas and small bowel) transplants were carried out at our centre.

Scientific collaboration has seen different models emerge to keep transplantation going through the pandemic. Chew et al., proposed a pragmatic four dimensional model of quadripartite equipoise to form a balanced framework and guide resource allocation during the pandemic 11 . The four limbs proposed were donor and graft safety, recipient outcomes, waitlist mortality and healthcare resources. The authors noted that as the pandemic waves progressed, there would be a shift in the balance towards and away from liver transplantation as based on a calculated quadripartite equipoise score. This was calculated for seven countries across several continents at the time, and corresponded with the stage of the pandemic they were in then.

Restoration of near normal donor activity was reported in the UK in June 2020 12 . By September, Italy and other European countries were in lockdown and the "UK Variant" mutated strain had been discovered. The UK was well and truly in the grip of the second wave by Christmas 2020, when lockdown was announced for the second time. While, published evidence is yet to be produced from the longer lasting second wave, with more severe restriction of services in the UK. Severea liver transplant centres were closed for adult transplantation for short periods of time, and some patients were transferred to alternative centres to allow them to undergo transplantation. However, a similar precipitous drop in the number of solid organ transplants was not noticed as the deceased donor pathway was maintained ( Figure-1) 12 . As the pressures on ICU eased in March 2021, most adult centres were able to undertake transplantation, albeit on a reduced scale compared to pre pandemic levels. Transplantation for children continued to remain unaffected during the second wave. .

Another evolving piece is on the vaccination front. There are now multiple available vaccines for COVID-19, and are all named differently in different parts of the world. Of interest in this scenario, is the AstraZeneca (AZD1222) vaccine. It carries with it, a 1 in 1,00,000 risk of developing a syndrome of thrombosis with thrombocytopenia, referred to as vaccine induced thrombosis and thrombocytopenia (VITT) 13 . The syndrome is characterised by thrombosis (most frequently cerebral venous sinus thrombosis), thrombocytopenia, high D-dimer levels (often along with low fibrinogen levels) and a positive ELISA for Platelet Factor 4 (PF4-Heparin induced thrombocytopenia test), despite the absence of prior heparin exposure 12 . Among the first reported series (from Germany), four out of nine patients had died. As with other immunological conditions, VITT carries a risk of passenger lymphocyte syndrome with it, i.e. the risk of transmitting immune cells that could trigger a similar auto-immune phenomenon in the naive recipient. At present, recipient outcomes are being monitored in the UK and caution is advised when using organs with high passenger lymphocyte burden e.g. liver, lung, small bowel and pancreas.

At the time of writing this editorial, India is in the throes of its second wave of the pandemic. There are reports of shortage of oxygen with heavily overstretched hospital resources, and there is call for international aid on these fronts. The impact of this debilitating second wave in India is likely to have a severe effect on delivery of transplantation services.

It remains to be seen what this pandemic, that has already taken over three million lives over almost 18 months, holds for the future. Liver transplantation has learnt from the first wave as demonstrated by Soin et al., and these lessons will be invaluable in shaping, not only the care for the immediate remaining duration of the pandemic, but, also for the long term future. It has indeed changed the way we practice medicine.

The COVID-19 outbreak in Italy: Initial implications for organ transplantation programs

Liver injury in COVID-19: management and challenges

How to guarantee liver transplantation in the north of Italy during the COVID-19 pandemic. A sound transplant protection strategy

One world, one pandemic, many guidelines: management of liver diseases during COVID-19

Ethical Issues in the COVID Era: Doing the Right Thing Depends on Location, Resources, and Disease Burden

Restructuring Living-Donor Liver Transplantation

Utilization of deceased donors during a pandemic: argument against using SARS-CoV-2-positive donors

Urgent Liver Transplantation Soon After Recovery From COVID-19 in a Patient With Decompensated Liver Cirrhosis. Hepatol Commun

Resuming liver transplantation amid the COVID-19 pandemic

The Lancet Gastroenterology and Hepatology

Resuming liver transplantation amid the COVID-19 pandemic

An international multicenter study of protocols for liver transplantation during a pandemic: A case for quadripartite equipoise

COVID-19: Advice for Clinicians -ODT Clinical -NHS Blood and Transplant

Guidance produced from the Expert Haematology Panel (EHP) focussed on syndrome of Thrombosis and Thrombocytopenia occurring after coronavirus Vaccination | British Society for Haematology

Figure-1: Trend in numbers of deceased donors and corresponding solid organ transplants in the UK since